Age-dependent differences in the immune response to human metapneumovirus
对人类偏肺病毒的免疫反应存在年龄依赖性差异
基本信息
- 批准号:10462114
- 负责人:
- 金额:$ 4.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-08-14
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAdoptive TransferAgeAlveolar MacrophagesBioinformaticsBiological AssayBody Weight decreasedBone MarrowCD8-Positive T-LymphocytesCD8B1 geneCell CommunicationCellsChestChildChimera organismClinicalCoculture TechniquesColorCommunicable DiseasesCoronavirusDataDevelopmentDichloromethylene DiphosphonateDiseaseElderlyEpigenetic ProcessExhibitsFlow CytometryFunctional disorderFundingGenesGenetic TranscriptionGoalsHospitalizationHuman MetapneumovirusImmuneImmune responseImmunityImmunocompromised HostImmunologicsImmunologyImpairmentIn VitroInfectionInflammatoryInfluenzaIsogenic transplantationKnowledgeLabelLaboratoriesLiposomesLiteratureLongevityLower Respiratory Tract InfectionLungMediator of activation proteinMolecular TargetMorbidity - disease rateMusNatural ImmunityNeonatalPathogenesisPathway interactionsPersonsPopulationPopulations at RiskPreventionPrimary InfectionPrincipal InvestigatorPulmonary InflammationReportingResearchResearch PersonnelRespiratory DiseaseRespiratory Tract InfectionsRespiratory syncytial virusRoleScientistSeasonsSeveritiesSeverity of illnessSignal TransductionT cell responseT-LymphocyteTechnical ExpertiseTestingTissuesTrainingTranslatingVaccinesViralVirusVirus ReplicationVulnerable PopulationsWeight GainWestern Blottingadaptive immunityage relatedagedbasecareercell typechromatin modificationclinically translatablecytokineexperimental studyfunctional disabilityimmunoregulationimprovedmacrophagemonocytemortalitymouse modelmultiple omicsneutralizing antibodynovelpreventprogrammed cell death protein 1reconstitutionrespiratoryrespiratory pathogenrespiratory virussecondary infectionsecondary lymphoid organskillstooltraining opportunity
项目摘要
ABSTRACT
Human metapneumovirus (HMPV) is a leading cause of lower respiratory infections in young children,
immunocompromised persons, and the elderly, resulting in high morbidity and mortality. Few studies have
investigated why HMPV is more severe in the elderly. This proposal aims to fill this knowledge gap about
HMPV pathogenesis. My preliminary data discovered that aged mice infected with HMPV exhibit delayed viral
clearance, increased lung inflammation, and increased CD8+ HMPV-tetramer+ cells co-expressing the
inhibitory markers PD-1, TIM-3, and LAG-3. I hypothesize that severe HMPV infection in the elderly is
caused by impairment of the CD8+ T cell response. In Aim 1, I will investigate the intrinsic causes of the
CD8+ T cell impairment observed in the aged host infected with HMPV using 10X Multiomics studies on murine
lung directly ex vivo and syngeneic transplants. 10X Multiomics will elucidate age-related epigenetic changes
in CD8+ T cells while syngeneic transplants will transfer young CD8+ T cells into an aged host and vice versa to
determine if CD8+ T cells are the primary immune cells causing the impaired immune response to HMPV (i.e.
increased weight loss, clinical severity, delayed viral clearance). In Aim 2, I will investigate extrinsic causes of
the CD8+ T cell impairment, namely by alveolar macrophages (AMs). I will use a 21-color multispectral flow
cytometry panel to enumerate M1 and M2 macrophage populations in the aged host. In vitro co-culture and
transwell assays of AMs and CD8+ T cells will determine if AMs directly impair CD8+ T cells. Selective depletion
of AMs in aged mice and adoptive transfer of young macrophages will determine how AMs contribute to the
impaired immune response in the aged host. 10X Multiomics will also be performed in this aim to investigate
the age-related epigenetic changes in AMs that may contribute to their aberrant M2 accumulation, which I have
also observed in my preliminary data.
This proposal aims to understand the mechanistic differences in the aged host response to HMPV,
which will help elucidate why HMPV infection in the elderly is more severe. These studies have the potential to
translate into the clinical setting and contribute to better management and treatment for HMPV infection, such
as immunomodulation. Identifying molecular targets in the aged host will guide development of a safe and
effective vaccine against HMPV for all at-risk populations.
In addition, this proposal has tremendous training opportunities, contributing towards my career goals of
becoming a clinician scientist and independent principal investigator in immunology and infectious disease.
摘要
人类偏肺病毒(HMPV)是幼儿下呼吸道感染的主要原因,
免疫功能受损的人和老年人,导致高发病率和死亡率。很少有研究发现
调查了为什么HMPV在老年人中更严重。这项建议旨在填补这一知识空白,
HMPV的致病机制。我的初步数据发现,感染HMPV的老年小鼠表现出延迟病毒感染
清除,增加肺部炎症,增加CD8+HMPV-四聚体+细胞共表达
抑制标记PD-1、TIM-3和LAG-3。我推测老年人中严重的HMPV感染是
由CD8+T细胞反应受损引起。在目标1中,我将调查导致经济衰退的内在原因
用小鼠10倍基因组学研究HMPV感染老年宿主CD8+T细胞损伤
肺直接体外移植和同基因移植。10倍多组学将阐明与年龄相关的表观遗传学变化
在CD8+T细胞中,同基因移植会将年轻的CD8+T细胞转移到老化的宿主中,反之亦然
确定CD8+T细胞是否是导致对HMPV免疫反应受损的主要免疫细胞(即
体重减轻、临床严重程度、病毒清除延迟)。在目标2中,我将调查外在原因
CD8+T细胞损伤,即肺泡巨噬细胞(AM)损伤。我会用21色的多光谱流
细胞计数仪板计数老年宿主中的M1和M2巨噬细胞群。体外共培养和
AM和CD8+T细胞的转井分析将确定AM是否直接损害CD8+T细胞。选择性耗竭
AM在老年小鼠中的作用和年轻巨噬细胞的过继转移将决定AM如何在
老年宿主的免疫反应受损。10倍多重组学也将在这个目标上进行研究
AM中与年龄相关的表观遗传学变化可能有助于它们异常的M2积累,我有
在我的初步数据中也观察到了。
这项建议旨在了解老年宿主对HMPV反应的机制差异,
这将有助于解释为什么老年人的HMPV感染更严重。这些研究有可能
转化为临床环境,有助于更好地管理和治疗HMPV感染,如
作为免疫调节剂。识别老龄宿主中的分子靶点将指导安全和
为所有高危人群接种有效的HMPV疫苗。
此外,这项提议有巨大的培训机会,有助于实现我的职业目标
成为免疫学和传染病领域的临床科学家和独立首席研究员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Olivia Parks其他文献
Olivia Parks的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Olivia Parks', 18)}}的其他基金
Age-dependent differences in the immune response to human metapneumovirus
对人类偏肺病毒的免疫反应存在年龄依赖性差异
- 批准号:
10700837 - 财政年份:2022
- 资助金额:
$ 4.85万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 4.85万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 4.85万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 4.85万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 4.85万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 4.85万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 4.85万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 4.85万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 4.85万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 4.85万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 4.85万 - 项目类别:














{{item.name}}会员




